# Allotera Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/allotera-therapeutics

- Industry: Biotechnology
- Headquarters: St. Louis, US
- Website: www.alloteratx.com
- Total disclosed funding: $222M
- Latest round: Series C (Jul 23, 2026)
- Investors on record: 13

## About

Based in Missouri, US, and founded in 2018, Wugen Inc. develops immuno-oncology cell therapies for tumors and heme malignancies. The company was co-founded by Dr. Todd Fehniger, Dr. John DiPersio, Dr. Melissa Berrien-Elliott, and Dr. Matthew Cooper, its Chief Scientific Officer. Dan Kemp is the current President and CEO of the company. In July 2026, Wugen Inc. raised an undisclosed amount of series C funding led by Fidelity Investments, with participation from Lightchain Capital, BioGenerator, and Blood Cancer United. The round was part of a larger USD 35 million series C and venture debt funding. The company's therapies aim to treat patients with cancer. The company is employing its patented technologies to manufacture WU-NK-101, a treatment for acute myelogenous leukemia that is currently in clinical trials (AML). It is also working on a pipeline of products aimed at solid tumor indications. Wugen Inc. plans to advance the clinical development of its NK Cell Platform and initiate studies on solid tumor indications.

## Funding rounds

- Series C, Jul 23, 2026, $14M — Fidelity Investments, BioGenerator, Lightchain Capital
- Series C, Aug 22, 2025, $109M — Abingworth, Intermediate Capital Group, RiverVest Ventures Partners, Aisling Capital, Fidelity Investments, Lyzz Capital, Lightchain Capital, Tybourne Capital Management
- Series B, Jul 15, 2021, $99M — Abingworth, Intermediate Capital Group, RiverVest Ventures Partners, Alexandria Venture Investments, Aisling Capital, Fidelity Investments, Alpha Wave Global, Velocity Capital, Sands Capital Alternatives, Lyzz Capital, Lightchain Capital, Tybourne Capital Management

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series B, Series C
- Intermediate Capital Group — Series B, Series C
- RiverVest Ventures Partners (https://capitalatlas.ai/funds/rivervest-ventures-partners) — Series B, Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series B, Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B, Series C
- Alpha Wave Global (https://capitalatlas.ai/funds/alpha-wave-global) — Series B
- Velocity Capital (https://capitalatlas.ai/funds/velocity-capital) — Series B
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Series B
- Lyzz Capital (https://capitalatlas.ai/funds/lyzz-capital) — Series B, Series C
- Lightchain Capital (https://capitalatlas.ai/funds/lightchain-capital) — Series B, Series C
- Tybourne Capital Management (https://capitalatlas.ai/funds/tybourne-capital-management) — Series B, Series C
- BioGenerator (https://capitalatlas.ai/funds/biogenerator) — Series C